The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Minocycline, nitrofurantoin, methyldopa, and infliximab are the most commonly implicated drugs in DI-ALH.
“Minocycline, nitrofurantoin, methyldopa, and infliximab are the most commonly implicated drugs”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [24]
DI-ALH has been well documented for minocycline, nitrofurantoin, hydralazine, methyldopa, interferon, imatinib, adalimumab and infliximab.
“DI-ALH has been well documented for minocycline, nitrofurantoin, hydralazine, methyldopa, interferon, imatinib, adalimumab and infliximab.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [24]
The liver damage in DI-ALH usually manifests clinically within 3 months of drug exposure, but can appear after more prolonged latency.
“The liver damage in DI-ALH usually manifests clinically within 3 months of drug exposure, but can appear after more prolonged latency.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [24]
Failure or late diagnosis in both DI-ALH and AIH can result in poor clinical outcomes.
“Failure or late diagnosis in both cases can result in poor clinical outcomes.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [24]
Resolution may not appear immediately and ongoing or even worsening liver injury can occur despite the withdrawal of the implicated drug.
“Resolution may not appear immediately and ongoing or even worsening liver injury can occur despite the withdrawal of the implicated drug.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [24]
Differentiating DI-ALH from AIH is crucial since most published studies suggest that DI-ALH often resolves spontaneously after withdrawal of the causative drug and affected patients rarely require long-term immunosuppression.
“Differentiating DI-ALH from AIH is crucial since most published studies suggest that DI-ALH often resolves spontaneously after withdrawal of the causative drug and affected patients rarely require long-term immunosuppression.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Björnsson, E. S., Bergmann, O. M., Björnsson, H. K., Kvaran, R. B., & Olafsson, S. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.006 · Cited by 865
Drug-Induced Acute Liver Failure: Results of a U.S. Multicenter, Prospective Study
Reuben, A., Koch, D. G., & Lee, W. M. (2010) · Hepatology · doi:10.1002/hep.23937 · Cited by 772
Genome-Wide Association Study Identifies Variants Associated With Autoimmune Hepatitis Type 1
de Boer, Y. S., van Gerven, N. M. F., Zwiers, A., Verwer, B. J., van Hoek, B., van Erpecum, K. J., Beuers, U., van Buuren, H. R., Drenth, J. P. H., den Ouden, J. W., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.04.022 · Cited by 304
Flagged first, then by citations
Research works printed but not linked: 30
- Wei, 2007, Acute liver failure in Sweden: etiology and outcome, J Intern Med, 262, 393, 10.1111/j.1365-2796.2007.01818.x · DOI
- Alvarez, 1999, International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis, J Hepatol, 31, 929, 10.1016/S0168-8278(99)80297-9 · DOI · Paper page
- Hennes, 2008, Hepatology, 48, 169, 10.1002/hep.22322 · DOI · Paper page
- Suzuki, 2011, The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury, Hepatology, 54, 931, 10.1002/hep.24481 · DOI · Paper page
- Czaja, 2011, Drug-induced autoimmune-like hepatitis, Dig Dis Sci, 56, 958, 10.1007/s10620-011-1611-4 · DOI · Paper page
- Bernal, 2007, The significance of autoantibodies and immunoglobulins in acute liver failure: a cohort study, J Hepatol, 47, 664, 10.1016/j.jhep.2007.05.011 · DOI
- Weiler-Normann, 2011, Drug induced liver injury and its relationship to autoimmune hepatitis, J Hepatol, 55, 747, 10.1016/j.jhep.2011.02.024 · DOI · Paper page
- Castiella, 2014, Drug-induced autoimmune liver disease: a diagnostic dilemma of an increasingly reported disease, World J Hepatol, 6, 160, 10.4254/wjh.v6.i4.160 · DOI · Paper page
- Licata, 2014, Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study, Dig Liver Dis, 46, 1116, 10.1016/j.dld.2014.08.040 · DOI · Paper page
- Björnsson, 2010, Drug-induced autoimmune hepatitis: clinical characteristics and prognosis, Hepatology, 51, 2040, 10.1002/hep.23588 · DOI · Paper page
- van Gerven, 2013, Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission, J Hepatol, 58, 141, 10.1016/j.jhep.2012.09.009 · DOI
- van Gerven, 2015, HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1, Genes Immun, 16, 247, 10.1038/gene.2014.82 · DOI
- Donaldson, 1991, Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors, Hepatology, 13, 701, 10.1002/hep.1840130415 · DOI
- Oliveira, 2011, Autoimmune hepatitis, HLA and extended haplotypes, Autoimmun Rev, 10, 189, 10.1016/j.autrev.2010.09.024 · DOI
- Chalasani, 2015, Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study, Gastroenterology, 148, 1340, 10.1053/j.gastro.2015.03.006 · DOI · Paper page
- Rockey, 2010, Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method, Hepatology, 51, 2117, 10.1002/hep.23577 · DOI · Paper page
- Fontana, 2009, Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct, Drug Saf, 32, 55, 10.2165/00002018-200932010-00005 · DOI · Paper page
- Hayashi, 2015, Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN), Liver Int, 35, 1623, 10.1111/liv.12540 · DOI
- Kleiner, 2014, Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations, Hepatology, 59, 661, 10.1002/hep.26709 · DOI · Paper page
- Zheng, 2014, HIBAG–HLA genotype imputation with attribute bagging, Pharmacogenomics J, 14, 192, 10.1038/tpj.2013.18 · DOI
- Gragert, 2013, Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry, Hum Immunol, 74, 1313, 10.1016/j.humimm.2013.06.025 · DOI
- Stricker, 1988, Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases, Hepatology, 8, 599, 10.1002/hep.1840080327 · DOI
- Malcolm, 1996, Minocycline-induced liver injury, Am J Gastroenterol, 91, 1641
- Goldstein, 2000, Minocycline as a cause of drug-induced autoimmune hepatitis: report of four cases and comparison with autoimmune hepatitis, Am J Clin Pathol, 114, 591, 10.1309/KV2J-VX6Q-L95V-VDE4 · DOI
- Toghill, 1974, Methyldopa liver damage, Br Med J, 3, 545, 10.1136/bmj.3.5930.545 · DOI
- Maddrey, 1975, Severe hepatitis from methyldopa, Gastroenterology, 68, 351, 10.1016/S0016-5085(75)80018-7 · DOI
- Forster, 1980, Hepatitis from hydralazine, N Engl J Med, 302, 1362, 10.1056/NEJM198006123022412 · DOI
- Meroni, 2010, ANA screening: an old test with new recommendations, Ann Rheum Dis, 69, 1420, 10.1136/ard.2009.127100 · DOI
- Frenzel, 2006, Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis, Am J Gastroenterol, 101, 2731, 10.1111/j.1572-0241.2006.00830.x · DOI
- Temple, 2006, Hy’s law: predicting serious hepatotoxicity, Pharmacoepidemiol Drug Saf, 15, 241, 10.1002/pds.1211 · DOI
Cited by
Sorted by citations
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
Drug-induced liver injury—types and phenotypes
Hoofnagle, J. H., & Björnsson, E. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1816149 · Cited by 652
Self-citationAASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines
Devarbhavi, H., Aithal, G., Treeprasertsuk, S., Takikawa, H., Mao, Y., Shasthry, S. M., Hamid, S., Tan, S. S., Philips, C. A., George, J., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10144-3 · Cited by 181
Andrade, R. J., Aithal, G. P., de Boer, Y. S., Liberal, R., Gerbes, A., Regev, A., Terziroli Beretta-Piccoli, B., Schramm, C., Kleiner, D. E., De Martin, E., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.033 · Cited by 166
Self-citationImmune-mediated drug-induced liver injury: immunogenetics and experimental models
Gerussi, A., Natalini, A., Antonangeli, F., Mancuso, C., Agostinetto, E., Barisani, D., Di Rosa, F., Andrade, R., & Invernizzi, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094557 · Cited by 87
The liver as a central "hub" of the immune system: pathophysiological implications
Ronca, V., Gerussi, A., Collins, P., Parente, A., Oo, Y. H., & Invernizzi, P. (2025) · Physiological Reviews · doi:10.1152/physrev.00004.2023 · Cited by 59
Metadata
- Authors
- de Boer, Y. S., Kosinski, A. S., Urban, T. J., Zhao, Z., Long, N., Chalasani, N., Kleiner, D. E., & Hoofnagle, J. H.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 15
- Issue
- 1
- Pages
- 103-112.e2
- ISSN
- 1542-3565
- PMC
- PMC5370577
- Cited by
- 190
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
